Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-013833

Director sold 1,270 shares at $23.74 ($30,150)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Heyman Richard A. Director 2024-05-16 Sale 10b5-1 −1,270 $23.74 $30,150 135,885 D: show line 1 in the form
Open-market sales · 1,270 sh · avg $23.74 · $30,150
Loading xslF345X05/form4-05202024_110525.xml…